Carcinoid Syndrome - Pipeline Insight, 2021
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Carcinoid Syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Carcinoid Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Carcinoid Syndrome: Overview
Carcinoid syndrome is a disease consisting of a combination of symptoms, physical manifestations, and abnormal laboratory findings. It is also known as carcinoid apudoma, carcinoid cancer, carcinoid disease, and functioning argentaffinoma. The signs and symptoms of carcinoid syndrome depend on which chemicals the carcinoid tumor secretes into your bloodstream. Carcinoid syndrome is caused by a carcinoid tumor that secretes serotonin or other chemicals into your bloodstream. Carcinoid tumors occur most often in the gastrointestinal tract, including your stomach, small intestine, appendix, colon and rectum. The pathophysiology of carcinoid syndrome is based on biologically active amines and peptides entering the systemic circulation and escaping the first-pass metabolism of the liver. Treatment modalities for carcinoid syndrome, include somatostatin analogs, liver-directed treatment therapy, surgical debulking for early-stage low-grade neuroendocrine tumors, and chemotherapy for the treatment of poorly differentiated neuroendocrine tumors or refractory carcinoid syndrome.
'Carcinoid Syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Carcinoid Syndrome pipeline landscape is provided which includes the disease overview and Carcinoid Syndrome treatment guidelines. The assessment part of the report embraces, in depth Carcinoid Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Carcinoid Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Carcinoid Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Carcinoid Syndrome Emerging Drugs
Further product details are provided in the report……..
Carcinoid Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Carcinoid Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Carcinoid Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Carcinoid Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Carcinoid Syndrome drugs.
Carcinoid Syndrome Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Carcinoid Syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Carcinoid Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Carcinoid Syndrome: Overview
Carcinoid syndrome is a disease consisting of a combination of symptoms, physical manifestations, and abnormal laboratory findings. It is also known as carcinoid apudoma, carcinoid cancer, carcinoid disease, and functioning argentaffinoma. The signs and symptoms of carcinoid syndrome depend on which chemicals the carcinoid tumor secretes into your bloodstream. Carcinoid syndrome is caused by a carcinoid tumor that secretes serotonin or other chemicals into your bloodstream. Carcinoid tumors occur most often in the gastrointestinal tract, including your stomach, small intestine, appendix, colon and rectum. The pathophysiology of carcinoid syndrome is based on biologically active amines and peptides entering the systemic circulation and escaping the first-pass metabolism of the liver. Treatment modalities for carcinoid syndrome, include somatostatin analogs, liver-directed treatment therapy, surgical debulking for early-stage low-grade neuroendocrine tumors, and chemotherapy for the treatment of poorly differentiated neuroendocrine tumors or refractory carcinoid syndrome.
'Carcinoid Syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Carcinoid Syndrome pipeline landscape is provided which includes the disease overview and Carcinoid Syndrome treatment guidelines. The assessment part of the report embraces, in depth Carcinoid Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Carcinoid Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Carcinoid Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Carcinoid Syndrome.
This segment of the Carcinoid Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Carcinoid Syndrome Emerging Drugs
- Paltusotine: Crinetics Pharmaceuticals
- AQST-305-SF: Aquestive Therapeutics
Further product details are provided in the report……..
Carcinoid Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Carcinoid Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Carcinoid Syndrome
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Carcinoid Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Carcinoid Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Carcinoid Syndrome drugs.
Carcinoid Syndrome Report Insights
- Carcinoid Syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Carcinoid Syndrome drugs?
- How many Carcinoid Syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Carcinoid Syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Carcinoid Syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Carcinoid Syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- Crinetics Pharmaceuticals
- Aquestive Therapeutics
- Entrinsic Biosciences
- Paltusotine
- AQST-305-SF
- Eenterade
Introduction
Executive Summary
Carcinoid Syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Carcinoid Syndrome – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Eenterade: Entrinsic Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Paltusotine: Crinetics Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Carcinoid Syndrome Key Companies
Carcinoid Syndrome Key Products
Carcinoid Syndrome- Unmet Needs
Carcinoid Syndrome- Market Drivers and Barriers
Carcinoid Syndrome- Future Perspectives and Conclusion
Carcinoid Syndrome Analyst Views
Appendix
Executive Summary
Carcinoid Syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Carcinoid Syndrome – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Eenterade: Entrinsic Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Paltusotine: Crinetics Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Carcinoid Syndrome Key Companies
Carcinoid Syndrome Key Products
Carcinoid Syndrome- Unmet Needs
Carcinoid Syndrome- Market Drivers and Barriers
Carcinoid Syndrome- Future Perspectives and Conclusion
Carcinoid Syndrome Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Carcinoid Syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Carcinoid Syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Carcinoid Syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Carcinoid Syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
